IGF-I in major depression and antidepressant treatment response

European Neuropsychopharmacology

Volumn 25, Issue 6, 2015, Pages 864-872

  Kopczak, Anna ^a   Stalla, Günter Karl ^a   Uhr, Manfred ^a   Lucae, Susanne ^a   Hennings, Johannes ^a   Ising, Marcus ^a   Holsboer, Florian ^a   Kloiber, Stefan ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Depression; Genetics; IGF I; Neuroendocrine dysfunction; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROCORTISONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGE; ARTICLE; BODY MASS; CHROMOSOME 15; CHROMOSOME 6; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; REMISSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; BLOOD; DEPRESSION; DRUG EFFECTS; GENETIC SCREENING; GENETICS; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SIGNAL TRANSDUCTION;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; GENETIC TESTING; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84929362306     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.013     Document Type: Article

References (37)

1. Benarroch E.E. Insulin-like growth factors in the brain and their potential clinical implications. Neurology 2012, 79:2148-2153.
2. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Pütz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Künzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Köhnlein O., Dabitz H., Brückl T., Müller N., Pfister H., Lieb R., Mueller J.C., Lõhmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
3. Bonfiglio J.J., Inda C., Refojo D., Holsboer F., Arzt E., Silberstein S. The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology 2011, 94:12-20.
4. Cerejeira J., Batista P., Nogueira V., Vaz-Serra A., Mukaetova-Ladinska E.B. The stress response to surgery and postoperative delirium: evidence of hypothalamic-pituitary-adrenal axis hyperresponsiveness and decreased suppression of the GH/IGF-1 axis. J. Geriatr. Psychiatry Neurol. 2013, 26:185-194.
5. Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone und insulin-like growth factor assays. Clin. Chem. 2011, 57:555-559.
6. Deuschle M., Blum W.F., Strasburger C.J., Schweiger U., Weber B., Körner A., Standhardt H., Gotthardt U., Schmider J., Pflaum C.D., Heuser I. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997, 22:493-503.
7. Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays-a 2009 update. Growth Horm. IGF Res 2010, 20:8-18.
8. GENDEP Investigators; MARS Investigators; STAR*D Investigators Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry. 2013, 170:207-217.
9. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., Dose T., Wollweber B., Spieler D., Messer T., Lutz R., Künzel H., Bierner T., Pollmächer T., Pfister H., Nickel T., Sonntag A., Uhr M., Ising M., Holsboer F., Lucae S. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr Res. 2009, 43:215-229.
10. Himmerich H., Zimmermann P., Ising M., Kloiber S., Lucae S., Kunzel H.E., Binder E.B., Holsboer F., Uhr M. Changes in the hypothalamic-pituitary-adrenal axis and leptin levels during antidepressant treatment. Neuropsychobiology 2007, 55:28-35.
11. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 1996, 17:187-205.
12. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
13. Horstmann S., Lucae S., Menke A., Hennings J.M., Ising M., Roeske D., Müller-Myhsok B., Holsboer F., Binder E.B. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
14. Ising M., Horstmann S., Kloiber S., Lucae S., Binder E.B., Kern N., Künzel H.E., Pfennig A., Uhr M., Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol. Psychiatry 2007, 62:47-54.
15. Jux C., Leiber K., Hügel U., Blum W., Ohlsson C., Klaus G., Mehls O. Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 1998, 139:3296-3305.
16. Kohli M.A., Lucae S., Saemann P.G., Schmidt M.V., Demirkan A., Hek K., Czamara D., Alexander M., Salyakina D., Ripke S., Hoehn D., Specht M., Menke A., Hennings J., Heck A., Wolf C., Ising M., Schreiber S., Czisch M., Müller M.B., Uhr M., Bettecken T., Becker A., Schramm J., Rietschel M., Maier W., Bradley B., Ressler K.J., Nöthen M.M., Cichon S., Craig I.W., Breen G., Lewis C.M., Hofman A., Tiemeier H., van Duijn C.M., Holsboer F., Müller-Myhsok B., Binder E.B. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 2011, 70:252-265.
17. Lesch K.P., Rupprecht R., Müller U., Pfüller H., Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr. Scand. 1988, 78:684-688.
18. Li R.S., Nakagawa Y., Liu Y.J., Fujisawa Y., Sai S., Nakanishi T., Chapman K.E., Seckl J.R., Ohzeki T. Growth hormone inhibits the 11 beta-hydroxysteroid dehydrogenase type 1 gene promoter activity via insulin-like growth factor I in HepG2 cells. Horm. Metab. Res. 2008, 40:286-288.
19. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S., Wray N.R., Lewis C.M., Hamilton S.P., Weissman M.M., Breen G., Byrne E.M., Blackwood D.H., Boomsma D.I., Cichon S., Heath A.C., Holsboer F., Lucae S., Madden P.A., Martin N.G., McGuffin P., Muglia P., Noethen M.M., Penninx B.P., Pergadia M.L., Potash J.B., Rietschel M., Lin D., Müller-Myhsok B., Shi J., Steinberg S., Grabe H.J., Lichtenstein P., Magnusson P., Perlis R.H., Preisig M., Smoller J.W., Stefansson K., Uher R., Kutalik Z., Tansey K.E., Teumer A., Viktorin A., Barnes M.R., Bettecken T., Binder E.B., Breuer R., Castro V.M., Churchill S.E., Coryell W.H., Craddock N., Craig I.W., Czamara D., De Geus E.J., Degenhardt F., Farmer A.E., Fava M., Frank J., Gainer V.S., Gallagher P.J., Gordon S.D., Goryachev S., Gross M., Guipponi M., Henders A.K., Herms S., Hickie I.B., Hoefels S., Hoogendijk W., Hottenga J.J., Iosifescu D.V., Ising M., Jones I., Jones L., Jung-Ying T., Knowles J.A., Kohane I.S., Kohli M.A., Korszun A., Landen M., Lawson W.B., Lewis G., Macintyre D., Maier W., Mattheisen M., McGrath P.J., McIntosh A., McLean A., Middeldorp C.M., Middleton L., Montgomery G.M., Murphy S.N., Nauck M., Nolen W.A., Nyholt D.R., O'Donovan M., Oskarsson H., Pedersen N., Scheftner W.A., Schulz A., Schulze T.G., Shyn S.I., Sigurdsson E., Slager S.L., Smit J.H., Stefansson H., Steffens M., Thorgeirsson T., Tozzi F., Treutlein J., Uhr M., van den Oord E.J., Van Grootheest G., Völzke H., Weilburg J.B., Willemsen G., Zitman F.G., Neale B., Daly M., Levinson D.F., Sullivan P.F. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 2013, 18:497-511.
20. McCarthy T.L., Centrella M., Canalis E. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells. Endocrinology 1990, 126:1569-1575.
21. Mehtonen O.P., Søgaard J., Roponen P., Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J. Clin. Psychiatry 2000, 61:95-100.
22. Moore J.S., Monson J.P., Kaltsas G., Putignano P., Wood P.J., Sheppard M.C., Besser G.M., Taylor N.F., Stewart P.M. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1999, 84:4172-4177.
23. Neggers S.J., van der Lely A.J. Modulation of glucocorticoid metabolism by the GH-IGF-I axis. Endocr. Dev 2011, 20:181-186.
24. Reinhardt R.R., Bondy C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology 1994, 135:1753-1761.
25. Rupprecht R., Rupprecht C., Rupprecht M., Noder M., Lesch K.P., Mössner J. Effects of glucocorticoids on the regulation of the hypothalamic-pituitary-somatotropic system in depression. J. Affect. Disord. 1989, 17:9-16.
26. Schilling C., Blum W.F., Heuser I., Paslakis G., Wudy S.A., Deuschle M. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J. Clin. Psychopharmacol. 2011, 31:390-392.
27. Sievers C., Schneider H.J., Stalla G.K. Insulin-like growth factor-1 in plasma and brain: regulation in health and disease. Front Biosci. 2008, 13:85-99.
28. Sievers C., Auer M.K., Klotsche J., Athanasoulia A.P., Schneider H.J., Nauck M., Völzke H., John U., Schulz A., Freyberger H.J., Friedrich N., Biffar R., Stalla G.K., Wallaschofski H., Grabe H.J. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur. Neuropsychopharmacol. 2014, 24:890-896.
29. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev. Neurobiol. 2010, 70:384-396.
30. Unterman T.G., Jentel J.J., Oehler D.T., Lacson R.G., Hofert J.F. Effects of glucocorticoids on circulating levels and hepatic expression of insulin-like growth factor (IGF)-binding proteins and IGF-I in the adrenalectomized streptozotocin-diabetic rat. Endocrinology 1993, 133:2531-2539.
31. Wang T., Zhou B., Guo T., Bidlingmaier M., Wallaschofski H., Teumer A., Vasan R.S., Kaplan R.C. A robust method for genome-wide association meta-analysis with the application to circulating insulin-like growth factor I concentrations. Genet. Epidemiol. 2014, 38:162-171.
32. Weber-Hamann B., Blum W.F., Kratzsch J., Gilles M., Heuser I., Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009, 42:23-28.
33. Werther G.A., Russo V., Baker N., Butler G. The role of the insulin-like growth factor system in the developing brain. Horm. Res 1998, 49(Suppl 1):37-40.
34. Wiethoff K., Bauer M., Baghai T.C., Möller H.J., Fisher R., Hollinde D., Kiermeir J., Hauth I., Laux G., Cordes J., Brieger P., Kronmüller K.T., Zeiler J., Adli M. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J. Clin. Psychiatry 2010, 71:1047-1054.
35. Wolkowitz O.M., Burke H., Epel E.S., Reus V.I. Glucocorticoids. Mood, memory, and mechanisms. Ann. N.Y. Acad. Sci 2009, 1179:19-40.
36. Young E.A., Haskett R.F., Murphy-Weinberg V., Watson S.J., Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry. 1991, 48:693-699.
37. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J. Psychiatr Res. 2001, 35:83-94.